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Summary. Transmissible spongiform encephalopathies
are a group of neural degenerative diseases that may be
infectious, sporadic, or hereditary and are associated
with an abnormally folded prion protein. Unfortunately
at the current time it is not at all clear what the normal
structure of the prion protein actually is or how it is toxic
to cells. 
Extensive research on prion diseases has led to a
dramatic increase in understanding of the pathogenesis
of prion disorders, which will hopefully lead to the
development of effective treatments. The inability to
detect the disease in blood using current technology has
made screening difficult. While fortunately there has
been a decline in the number of clinical cases of
transmissible variant CJD, evidence indicates that very
long incubation periods can occur in humans so there
may be a long slow, gradual epidemic. In particular,
clinical cases in genotypes other than those homozygous
for methionine at codon 129 of PRNP have not yet
occurred, but such cases might be expected to have
longer incubation periods and show differences in
pathology to those seen to date.
Transgenic animal studies have shown that a large
proportion of infected animals develop sub-clinical
disease. Moreover, results from a large prevalence study
in humans show that several cases test positive but do
not develop clinical disease. It is possible therefore that
further cases of secondary transmission could occur by
iatrogenic spread, which could result in vCJD persisting
in the UK at low levels for many years, highlighting the
importance of continued vigilance.
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Introduction
Creutzfeldt-Jakob disease (CJD), first described by
Creutzfeldt and Jakob in the 1920s, is a rare, fatal brain
disorder associated with the presence of a misshapen
protein known as a prion protein. The term prion was
derived from the words “proteinaceous infectious
particle” in 1982 by Nobel Prize winner, Stanley B.
Prusinera.
CJD belongs to transmissible spongiform
encephalopathies (TSE's), a group of progressive
neurodegenerative conditions that include Creutzfeldt-
Jakob Disease (CJD), variant Creutzfeldt-Jakob Disease
(vCJD), Gerstmann-Sträussler-Scheinker disease (GSS),
Fatal Familial Insomnia (FFI), Kuru- in humans and
Scrapie in sheeps, Bovine Spongiform Encephalopathy
(BSE) or "Mad Cow Disease" in cows, transmissible
mink encephalopathy (TME), and chronic wasting
disease (CWD) in mule deer and elk. TSE may be
infectious, sporadic, or hereditary (Hilton, 2006).
CJD occurs worldwide at a rate of about 1 case per
million people per year. From 10 to 15 percent of CJD
cases are inherited as an autosomal dominant disorder.
Familial Creutzfeldt-Jakob disease occurs in unusually
high frequency in Chileans (Masters et al., 1979) and is
particularly high amongst Libyan Jews (Kahana et al.,
1974). The disease usually develops in a person between
the ages of 55 and 65 years. In more than 85 percent of
cases, the duration of CJD is less than 1 year (median: 4
months) after onset of symptoms (Knight and Will,
2004).
The sporadic form of the disease accounts for around
80 percent of people who develop CJD world-wide
(Hilton, 2006). The sporadic disease presents in patients
as a rapidly progressive dementia. In the majority of
cases the length of the illness is under six months in
contrast to other prion diseases which generally have a
longer duration. Clinical features of CJD include a
neurological presentation, with dementia, and a
progressive cerebellar syndrome including ataxia, gait,
Review
Current concepts in human prion protein 
(Prp) misfolding, Prnp gene polymorphisms and 
their contribution to Creutzfeldt-Jakob Disease (CJD)
K. Michalczyk and M. Ziman
School of Exercise, Biomedical and Health Science, Edith Cowan University, Joondalup, Western Australia, Australia
Histol Histopathol (2007) 22: 1149-1159
Offprint requests to: Dr. Mel Ziman, School of Exercise, Biomedical and
Health Science, Edith Cowan University, 100 Joondalup Drive,





Cellular and Molecular Biology
and speech abnormalities and seizures. In most patients,
these symptoms are followed by involuntary movements
and the appearance of a typical diagnostic
electroencephalogram tracing (Knight and Will, 2004).
Variant CJD (vCJD) was first described in 1996 in
the United Kingdom. Epidemiologic and laboratory
evidence indicate that vCJD in humans is caused by
transmission of the agent causing BSE in cattle via
consumption of BSE-contaminated cattle products
(Brown et al., 2001; Belay and Schonberger, 2002). The
variant form of CJD has several different characteristics
(Brown et al., 2001; Belay and Schonberger, 2002); the
median age at death for vCJD patients is 28 years,
compared with 68 years for patients with classic CJD. In
addition, all vCJD cases have neuropathologic findings
distinctly different from those of classic CJD (Ironside,
1998), and all have had a particular genetic profile i.e.,
homozygosity for methionine at codon 129 of the prion
protein gene (Will et al., 2004). Thus, cases of vCJD can
be distinguished from classic CJD on the basis of
clinical, genetic and pathologic data. 
The diagnosis of prion diseases, especially CJD is
difficult because the clinical symptoms are nonspecific
and sometimes variable. Moreover, imaging, EEG and
other laboratory tests are not unequivocal.
Neuropathological studies are needed but their
interpretation may be ambiguous. Transmissible
spongiform encephalopathies (TSEs) are characterised
by neurodegenerative processes with characteristic
spongiosis. However, vacuolization similar to that in
TSE-spongiosis may occur in some CNS disorders or in
putrescent brain tissue. In some cases of CJD,
particularly those of long duration, neuronal loss and
astrocyte proliferation can mask the presence of
spongiform changes, especially when vacuoles are not
numerous. The only certain diagnostic marker for TSE is
the presence of PrPSc, the misfolded prion protein that is
believed to be the direct cause of all TSEs (Zaborowski,
2004).
The human prion protein gene (PRNP)
The human gene (PRNP) that encodes the prion
protein (PrP) was first identified in scrapie-infected
rodents. It is a single-copy chromosomal gene and the
protein is encoded from a single exon. In addition to the
protein-coding exon (exon 3), PrP genes in mammals
contain one (humans) or two (sheep and mice) 5’
noncoding exons that are included in the final mRNA
(Lee et al., 1998) (Fig. 1). Further upstream, the
promoter region of the human PRNP gene is a well
characterized region that is highly GC-rich, lacks a
canonical TATA box, contains a CCAAT box, and has a
number of putative binding sites for transcription factors
SP1, AP1 and AP2 (Mahal et al., 2001).
The structure of the PRNP gene and mRNA
The nucleotide sequence of human PRNP,
determined from cosmid clone pGPRP1 (Puckett et al.,
1991), is 35,522bp in length. The gene has two known
exons (134 and 2355 nucleotides in length) separated by
an intron of 12,696 bases, and a dG + dC content of
44.1%. A 1-kb region around exon 1 forms a "CpG
island" (Fig. 1) (Lee et al., 1998), as found 5’ of the
transcriptional start site of many housekeeping genes 
There are also two repeats in the human PRNP gene
locus (MER74 and MER88; Fig. 2) that are related to
two consensus sequences in the human repeat database
(MER73 and MER54) (characteristic of viral LTRs
(Long Terminal Repeats), having TG...CA terminal
dinucleotides flanked by 5-bp insertion site duplications
(Smit and Riggs, 1995). 
In fact, a large percentage of the human PRNP locus
appears to be derived from mobile elements; there are
several short interspersed repetitive element (SINE), and
long interspersed repetitive element (LINE) insertions in
the PRNP gene (Smit, 1996; Smit et al., 1996).
Interestingly, 14 of the 15 SINEs (Alu sequences) belong
to subfamilies (AluSx, AluJ, and monomers) thought to
be >35 million years old (Smit and Riggs, 1995;
Kapitonov and Jurka, 1996).
From a comparison of human, sheep and mouse
PRNP/Prp genes, it is clear that there are common sites
of integration of known classes of transposable elements
or processed pseudogenes (Fig. 2). Insertion of these
elements since the mammalian radiation has increased
the size of the human PRNP locus by 20% and both the
mouse and sheep loci by 41% although some large
deletions have partially reversed this size increase. In
almost all cases, repetitive sequences belonging to
subfamilies predicted to predate the mammalian
radiation are found at orthologous sites in all species,
whereas predicted younger elements are generally found
in only one species. 
The exonic structure of the human gene differs from
that of other mammals. While the first exon and the
beginning of intron 1 are poorly conserved, there is a
highly conserved region of 99-bp present in human
DNA, 2303 bp after exon 1. This region is 82% and 81%
identical to exon 2 of sheep and mouse, respectively
(Fig. 3) (Lee et al., 1998). However this gene region
does not appear to be encoded in humans as it is not
present in any human PRNP mRNAs analyzed to date
even though this human exon 2-like sequence is flanked
by consensus splice donor and acceptor sites similar (but
not identical) to those in the mouse and sheep genes.
Also, since the exon 2-like sequence does not contain a
translation start codon (ATG) in the correct translational
reading frame with human PRNP exon 3, it forms part of
the UTR of human RNA. 
All human PRNP cDNAs isolated to date have exon
1 spliced directly to exon 3 (using the exon numbering
system of the sheep and mouse PrP genes). It is possible
that nucleotide substitutions at the donor splice site in
the human gene (as indicated in Fig. 3B) are responsible
for the absence of exon 2 since the acceptor splice site is
typical and highly conserved. The conservation of the
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first half of exon 2 in the human sequence is possibly
caused by the presence of transcription factor binding
sites at this locus. Baybutt and Manson (1997) have
shown that the last 550 bp of intron 1 is important for
promoter activity of the mouse PrP gene, and it is
possible that this functional region extends into exon 2
(Lee et al., 1998).
Alternatively, the human exon 2 could be included
within a subset of mRNAs from tissues that have not yet
been analyzed. This possibility is compatible with
observed tissue specific alternate exon 2 splicing of PrP
in other mammals; exon 2-containing transcripts have
been described in cattle (Yoshimoto et al., 1992) and in
the Syrian hamster (SHa) PrP gene, for which exon 1
originally appeared directly spliced to exon 3 (Basler et
al., 1986). Whereas 90% of brain SHaPrP mRNAs
exhibit exon 1-3 splicing, 10% include exon 2 sequences
similar to those of sheep and mouse (Li and Bolton,
1997). Interestingly, an increased abundance of exon 2-
containing mRNAs was observed in brain mRNA of
scrapie-infected hamsters, which may reflect preferential
expression in astrocytes (which become activated during
the course of prion infections).
The PrPc protein
The normal prion protein, PrPc, encoded by exon 3
of the prion gene (PRNP), is produced in prion diseases,
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Fig. 1. A. The human PRNP gene is located on chromosome: 20; Maps: 20pter-p12 (NCBI Entrez Gene). B. Structure of the PrP gene and its mRNA.
Exons are shown in light blue and the coding region (entirely contained in exon 3) is shown in dark blue (NCBI Entrez Gene). C. A summary of features
found at PrP loci. (A) The human PrP locus. (B) The sheep PrP locus. (C) The mouse locus (Prnp (A-C) (1) The positions of the exons in each species.
The scale is in kb. (2) The frequency of observed CpG dinucleotides divided by frequency of expected CpG. An unusually high CpG frequency is found
in the promoter region of each PrP gene. The mouse PrP gene has a second high CpG region in intron 2 (3) Simple repeats at least 10 nucleotides in
length (derived from Lee et al., 1998).
from the normal host gene but undergoes an
incompletely understood post-translational
conformational change to a disease related form, PrPSc.
The function of normal PrPc is not known but it may
have roles in anti-oxidant systems and cellular copper
metabolism (Knight and Will, 2004) although within the
nervous system, it may have a role in synaptic function
as PrP-knockout mice show impaired GABA-mediated
synaptic inhibition and reduced long-term potentiation
(Collinge et al., 1994; Manson et al., 1995). 
The normal PrPc protein is a glycoprotein that is
attached to the plasma membrane by a glycosyl
phosphatidylinositol anchor (Prusiner, 1998). It is
present in cells of the central nervous system
(Kretzschmar et al., 1986; Stahl et al., 1987, 1990) and
in muscle cells (Brown et al., 1998). In neurons prion
protein is mainly localized at synaptic terminals, in
cholesterol-rich microdomains of the plasma membrane
known as caveolae (Prusiner, 1998). PrPc is composed
of approximately 250 residues, and is proteolytically
processed to remove a 22-residue N-terminal signal
peptide and a 23 C-terminal amino acid segment after
addition of the glycosyl phosphatidylinositol (GPI)
anchor to Ser-231 (Prusiner, 1996, 1997). Molecular
modeling studies indicate that PrPc contains several α-
helical regions of secondary structure (Gasset et al.,
1992; Huang et al., 1994). The processed protein
contains a 179-214 disulfide crosslink and glycosylation
sites at Asn-181 and Asn-197. A protease resistant core
present between residues 90-231, is sufficient to transmit
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Fig. 2. Comparison of the human, sheep, and mouse PRNP/PrP loci. The complete sheep and human sequences are shown, whereas the Prp mouse
cosmid sequence extends 2.5 kb upstream of the aligned regions. Deletions in the genome >250 bp are indicated by brackets. Identified interspersed
repeats are represented by four differently shaded arrows for the four major classes of repeats: SINEs, LINEs, LTR elements, and DNA transposons.
Wide arrows are used for elements that are absent at the orthologous sites in the other two species and thus probably integrated after the mammalian
radiation. Older elements are indicated with thinner arrows. The indicated shared interspersed repeats are usually not detectable in the mouse genome
(and sometimes not in the sheep genome) by direct comparison with the repeat consensus sequence but could be inferred from the alignment with
human DNA. A measure of similarity between the human and either sheep or mouse sequences, depicted by a graph above and below the human
sequence, respectively. Regions outside the coding region that are conserved between all species are indicated with an asterisk (*) (derived from Lee
et al., 1998).
infectivity when misfolded. 
Postranlational modifications producing a mature
PrPc
The co- and posttranslational modifications of PrPc
are initiated by the cleavage of the N-terminal signal
peptide (aa 1-22) and the attachment of core glycans
while the nascent chain is still associated with the
translocon. Shortly after the protein is fully translocated
the GPI anchor is attached to the acceptor amino acid
close to the C terminus. The final maturation of PrPc
includes the processing of the core glycans into complex
type glycans by a series of enzymatic reactions in the
endoplasmic reticulum (ER) and Golgi compartment.
Experiments in which the N-terminal domain of PrPc is
deleted show that this region is not essential and has no
impact on the formation of complex glycosylated and
GPI-anchored PrPc. By contrast, α-helix 1 is essential
for GPI anchoring and complex glycosylation.
Moreover, a single amino acid substitution in helix 3 can
cause a loss of the GPI anchor possibly due to
interactions between helix 1 and helix 3 (Pekari and
Schmidt, 2003).
The GPI anchor signal sequence, the attachment of
the GPI anchor and membrane anchorage of PrPc are all
necessary for the terminal processing of glycans.
However, complex glycosylation is not specific for GPI-
anchored PrP; PrP-CD4 in which PrP is fixed to the
membrane via the heterologous CD4 transmembrane
domain is complex-glycosylated as well. In the absence
of a membrane anchor, terminal glycosylation does not
take place indicating that membrane anchoring provides
a specialized environment (i.e. the membrane surface
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Fig. 3. Alignments of sequences outside the PrP coding regions conserved between the human, mouse, and sheep. The most conserved regions are
blocked. A. There are two conserved sections of intron 1 that may be involved in transcriptional regulation. Both sites are within a conserved LINE1
element (Fig. 2). However, in the sheep gene they all diverge from the consensus binding sites. Baybutt and Manson (1997) identified transcriptional
suppressor activity between bases 9744 and 9932 and promoter activity between bases 10,114 and 10,307 of the mouse sequence, suggesting that
the second, highly conserved block (bases 10,200-10,233 in mouse) may be involved in transcriptional activation. B. Alignment of the human, sheep,
and mouse PrP gene exon 2 regions. Comparison of the exon 2 splice sites shows that the donor site is quite distinct in sheep and mouse but has
become indistinct in the human genome because of the presence of C and A at positions 4 and 5. The donor site consensus and that of the other
species (including cow, rat, and hamster; data not shown) contain a purine and G. C. A 40-bp block ~100 bp before the polyadenylation site in the PrP
gene is highly conserved between four mammalian species. D. In the 3' flanking region of the PrP gene are two small blocks of conserved sequences
lying within an ancient DNA transposon, called MER5a. There are three other conserved regions: one 500 bp upstream of "exon 2" (Fig. 3A), one at the
3' end of the transcripts (Fig. 3C), and one 3-4 kb downstream of the polyadenylation site (Fig. 3D). (Derived from Smit and Riggs, 1995)
may be necessary for native folding of PrPc (Pekari and
Schmidt, 2003).
PrPc protein misfolding 
The pathogenic form of the protein is referred to as
PrPSc (PrP Scrapie) or PrPRes (protease resistant
protein). The conversion of PrPcÕPrPSc, the pathogenic
form, is a late post-translational process, occurring after
PrPc has reached its normal cellular location. In contrast
to PrPc which is largely α-helical, PrPSc is characterized
by a high content of ß-sheet structures (Caughey et al.,
1991a,b; Gasset et al., 1993), partial resistance to
proteolytic digestion, and a propensity to aggregate into
insoluble amyloid-like fibrils and plaques (Prusiner,
1998; Torrent et al., 2003, 2004). 
The exact mechanism of conversion of PrPc into
PrPSc is unclear; however, it is clear that PrPSc
autocatalyses the process (Kocisko et al., 1994). Two
mechanisms of propagation have been suggested. One
model advocates template-directed refolding (Aguzzi et
al., 2001), whereby exogenously introduced PrPSc
interacts with PrPc to cause a conformational change of
PrPc into PrPSc, overcoming a high energy barrier that
would normally prevent the spontaneous conversion.
The second proposed mechanism, ‘seeding’ or
‘nucleation polymerization’, suggests that PrPSc and
PrPc are in a thermodynamic equilibrium from which
PrPSc can be recruited to a more stable crystal-like
‘seed’ composed of several precursor PrPSc molecules
(Jarrett and Lansbury, 1993). Studies in transgenic mice
indicate that a protein chaperone facilitates the
conversion of PrPSc from PrPc (Telling et al., 1995).
Recent studies using highly purified PrPSc have
demonstrated its ability to transmit disease (Castilla et
al., 2005), lending strong support to the ‘protein-only’
hypothesis of transmission. Furthermore the presence of
PrPSc correlates with disease transmissision and
endogenous PrPc is a requirement for the development
of the disease (Brandner et al., 1996a,b) which can be
decreased with anti-PrP antibodies (Gabizon et al.,
1988). Changes in neural electrophysiology seen in PrP-
knockout mice (Collinge et al., 1994; Manson et al.,
1995) are similar to those seen in scrapie-infected mice
(Jefferys et al., 1994), in keeping with a ‘loss of
function’ effect. However, in vitro, neural toxicity does
not always correlate with conversion to PrPSc and the
mechanism by which PrPSc causes neurodegeneration is
unclear (Ma et al., 2002).
Covalent reaction of the intramolecular disulfide
bond of PrPc to form PrPSc
PrPcÕPrPSc conversion is proposed to involve
disulfide polymerization, by which the terminal thiolate
group of a PrPSc polymer attacks the intramolecular
disulfide bond of a PrPc monomer, so that an
intermolecular disulfide bond is formed, thus
lengthening the PrPSc polymer while maintaining a
terminal thiolate group (Welker et al., 2001). The initial
thiolate attack is facilitated by the experimentally
observed association of the PrPc monomer and PrPSc
polymer (Horiuchi and Caughey, 1999; Horiuchi et al.,
2000), which may destabilize the tertiary structure and
the intramolecular PrPc disulfide bond. The subsequent
conformational transition to the ß-enriched scrapie
isoform evidently protects the intermolecular disulfide
bond (Muramoto et al., 1996; Herrmann and Caughey,
1998), inhibiting the back-reaction of depolymerization.
Thus, in this model, the smallest infectious unit is an
oligomer of PrPSc that protects its intermolecular
disulfide bond(s) from thiolate attack and has at least
one free thiolate at which the PrPcÕPrPSc conversion
can occur (Welker et al., 2001).
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Fig. 4. Possible pathways for the formation of
PrPSc via an intermediate state that is critical
for prion formation (derived from Kelly, 1998).
A proposed mechanism for protein conformational
change 
Kelly (1998) proposed that formation of a weak
dimer of PrPc (90-231), which can occur according to
analytical equilibrium ultracentrifugation studies (James
et al., 1997), could be very important in converting PrPc
into the prionogenic state through tertiary and quaternary
structural changes (Fig. 4). Such an assembly process
may be necessary to partially or almost completely
unfold PrPc to form the prionogenic intermediate as in
the conversion of transthyretin to amyloid fibrils or in
the conversion of the lysozyme variants into amyloid
respectively (Colon and Kelly, 1991, 1992; Kelly, 1996-
1998; Sunde et al., 1997; Torrent et al., 2004). However,
while these mechanisms are proposed to produce a
PrPSc fibrillar structure similar to amyloid, in fact little
is known about the structural details of PrPSc other than
that it is richer in ß-sheet structure than PrPc (Lansbury,
1992; Kelly, 1997; Prusiner, 1996, 1997).
Kinetic intermediate 
A study by Apetri and Surewicz (2002) provided
evidence that the prion protein folds into its native state
via a rate-limiting, three-state mechanism involving a
monomeric intermediate (Fig. 4). This early intermediate
appears to be relatively compact and especially stable
under acidic conditions. In addition to its role in normal
prion protein folding, the folding intermediate is also
likely to be of major importance in the PrPcÕPrPSc
conversion.
The partially folded PrP intermediate is more stable
than the fully unfolded protein. This, combined with a
relatively high hydrophobicity and aggregation
propensity typical of folding intermediates, renders the
intermediate state of PrP a better candidate than the
unfolded state as a direct monomeric precursor of PrPSc.
The role of a folding intermediate in the PrP conversion
is in line with the finding that the transition of the
recombinant prion protein to a scrapie-like form is
strongly promoted in the presence of relatively low
concentrations of urea, i.e. under conditions that would
increase the population of an intermediate state (Morillas
et al., 2001). In contrast, conditions favoring the native
state (no denaturant), or those that shift equilibrium
toward the fully unfolded state (high concentration of
urea), are not conducive to the conversion reaction
(Morillas et al., 2001). It should also be noted that the in
vitro transition of the recombinant PrP to a scrapie-like
form appears to be especially effective at low pH
(Swietnicki et al., 1997; Hornemann and Glockshuber,
1998). This correlates well with the observation that
acidic pH stabilizes the intermediate during the prion
protein folding reaction. The PrPcÕPrPSc conversion in
mildly acidic conditions has implications for prion
disease pathogenesis since it is reported that this
conversion may take place in acidic compartments of the
cell (Caughey et al., 1991a,b).
Amyloid fibril formation
The reason for the toxicity of PrPSc is unkown.
Recent in vitro evidence provides a clue since high-
pressure treatment can trigger formation of ß-sheet-rich,
protease-resistant, insoluble prion protein structures
known as amyloid aggregates (Torrent et al., 2004). At a
low protein concentration range and pressures greater
than 450 MPa, a metastable intermediate structure,
probably a soluble oligomer, is formed (Torrent et al.,
2003). At a higher protein concentration (typically 2
mg/mL), the intermediate undergoes further
conformational changes and aggregates irreversibly, with
the hydrophobic parts of the prion protein becoming
water exposed. The protein part undergoing this
structural change is probably the region containing
residues 90-167, which encompasses helix 1 and the
flexible unstructured N-terminal part of the molecule. It
appears that high pressure does not completely unfold
PrP, but instead induces a misfolded conformation
containing water-exposed hydrophobic domains. At a
sufficiently high protein concentration (>2 mg/mL)
intermolecular collapse of these domains eventually
provokes protein aggregation (Torrent et al., 2004).
Fluorescence and electron microscopy, suggests that
the aggregates, formed after transient high pressure
treatment and decompression, can be classified as pre-
amyloid structures with a strongly increased ß-sheet
content with respect to the native form, and an increased
resistance to proteolysis (similarly to the infectious
PrPSc form). It is therefore possible that the pre-amyloid
form contributes to pathogenesis or is itself infectious
(Torrent et al., 2004).
Different proteins do not however, follow the same
unfolding pathways (Balny et al., 2002), resulting in
different unfolded states which, in some cases, have the
tendency to aggregate. Amyloid propagation is normally
highly sequence specific. In PrP, this specificity leads to
the “species barrier” phenomenon, which obstructs or
slows down transmission (Scott et al., 1993; Telling et
al., 1995; Gabizon and Taraboulos 1997; Raymond et al.,
1997; Baskakov, 2004). Accordingly, a specific pattern
of molecular interactions, rather than nonspecific
interactions, play a role in the formation of amyloid
structures. It has been demonstrated by Van Eldik et al.,
(1989) that side-chain hydrogen bonds and aromatic
stacking play an important role in the stabilization of
amyloid structures. They suggested that stacking
interactions and/or stabilized hydrogen bonds between
newly formed ß-sheet strands may contribute
energetically as well as directionally in the assembly of
well-packed amyloid structures. More research is
required to establish the presence and the role of these
structures in TSE related neurodegenerative diseases.
Alternate allelic forms of PrP affect amyloid
formation and disease susceptibility
The human PrP gene (PRNP) has two common
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allelic forms that encode either methionine or valine at
codon 129. This polymorphism modulates disease
susceptibility and the clinico-pathological phenotypes in
sporadic and acquired prion diseases (Collinge et al.,
1991; Palmer et al., 1991; Brown et al., 2001; Mead et
al., 2001) and may affect age of onset (Baker et al.,
1991; Cervenakova et al., 1998; Parchi et al., 1999). All
tested cases of variant CJD, to date, have been
homozygous for codon 129-MetMet which is in contrast
to an overall prevalence of 37% for this genotype in
Caucasian populations, indicating a strong genetic risk
factor. It is, however, possible that cases with an
alternative codon 129 genotype may occur in the future
as variations at this locus may influence incubation
period (Parchi et al., 1999).
The molecular mechanisms by which the effect of
this polymorphism is mediated remain unclear
(Baskakov et al., 2005). Residue 129 is within the first
ß-strand (residues 128–131) in human PrP and might be
a ‘nucleation site’ for a conformational transition from
PrPc to PrPSc involving the loops connecting the ß-sheet
to the first helix (Riek et al., 1996, 1997). The folding,
dynamics and stability of the physiological, α-helix-rich
form of recombinant PrP are not affected by codon 129
polymorphism. In contrast, the misfolding pathway
leading to the formation of ß-sheet-rich, oligomer is
favoured by the presence of methionine, compared with
valine, at position 129. An alternative folding pathway,
of amyloid formation, is favoured by the valine 129
allelomorph, forming amyloid fibres with a considerably
shorter lag phase than the methionine 129 allelomorph
whether under spontaneous conditions or when seeded
with pre-formed amyloid fibres. Taken together, these
studies demonstrate that the effect of the codon 129
polymorphism depends on the specific misfolding
pathway and on the initial conformation of the protein.
The inverse propensities of the two allelomorphs to
misfold as shown in vitro through the alternative
oligomeric and amyloidogenic pathways could explain
some aspects of prion diseases linked to this
polymorphism such as age at onset and disease
incubation time (Fasman 1998; Santini et al., 2003;
Baskakov et al., 2005; Tahiri-Alaoui and James, 2005).
The codon 129 polymorphism may also influence
the clinical phenotype (including age of onset and illness
duration) of genetic prion diseases – ie diseases arising
from a mutation in the PrNP gene. Most notably, the
D178N mutation gives rise to a clinical picture of
genetic CJD when associated with 129-Val on the mutant
allele and yet results in FFI when associated with 129-
Met. 
The converse propensities of the 129-Met and 129-
Val allelomorphs to fold into ß-oligomer and amyloid
forms in vitro, respectively, is highly intriguing, given
the effect of the polymorphism on disease susceptibility
in vivo. The differences in the misfolding behaviour
between 129-Met and 129-Val could form the basis of
human TSEs, particularly sporadic CJDs, that are
associated with codon 129 variations such as age at
onset of the disease and incubation time (Laplanche et
al., 1994; Parchi et al., 1999; Schulz-Schaeffer et al.,
1996; Windl et al., 1996; Alperovitch et al., 1999; Hauw
et al., 2000). Reports mainly suggest that the age at onset
is lower and the disease duration longer in 129-Val
cases. This effect appears to be replicated in animal
models of human disease: two out of three transgenic
mice expressing human PrP 129-Val showed a shorter
incubation period (Hill et al., 1997) as compared with
transgenic mice expressing human PrP Met129 (Asante
et al., 2002) when challenged with a matching genotype
inocula. 
Of concern are the findings in transgenic studies that
a large proportion of infected animals develop sub-
clinical disease (Asante et al., 2002; Wadsworth et al.,
2004). Taken together with results from a large
prevalence study in humans (Hilton et al., 2004) which
suggests the presence of subclinical disease, it is
possible that these individuals could act as a reservoir of
carriers in the population and potentially cause further
cases of secondary transmission which could result in
vCJD persisting in the population at low levels for many
years. 
Conclusion
Although the cellular prion protein is remarkably
well conserved in mammals, discerning the function(s)
of this small protein has proved challenging. Indeed,
PrPc is a case study in protein structural anomolies.
There may now be sufficient experimental ‘fragments’ to
begin assembling the larger picture of PrPc function, and
to understand the origins and pathogenesis of prion
disorders. This, along with developments in
immunotherapy, gene therapy and proteomics, may
allow design of intervention strategies to halt the
progression of prion diseases.
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